Singh, PushpendraBast, FelixKumar, ShashankSaini, Khem Chand2018-01-022024-08-132018-01-022024-08-132017SINGH, P, BAST, F, KUMAR, S, SAINI, KC (2017) Influence of Insulin and Metformin on Prostate Cancer. In book: Horizons in Cancer Research., Editors: Hiroto S. Watanabe Vol. 64 pp 1-10 Nova Science Publishers.978-1-53610-512-4http://10.2.3.109/handle/32116/428Dietary habit and hormonal factor play a significant role in prostate cancer deregulation in addition to genetic and environmental factor. Nonandrogenic growth factor like insulin and insulin growth factor are influences the prostate cancer initiation and progression. Insulin and Insulin-like growth factor regulate various metabolic pathways, cell growth, cellular proliferation and apoptosis. Various epidemiological results point out that insulin not only increased the risk of cardiovascular, macrovascular, and microvascular complications but also at significantly increase the risk of various cancers. The use of metformin, the usually approved drug for type 2 diabetes, was continually linked with the decreased risk of the incidence of a variety of cancers. More than 60 clinical trials of metformin being tested as a treatment for various types of cancer, including breast, colon, prostate, endometrial, and pancreatic cancer. The ability of metformin to lower circulating insulin may be predominantly imperative for the treatment of cancers. Moreover, metformin inhibiting mammalian target of rapamycin promoted cell growth signaling. In this chapter, the confirmation behind a role for metformin in cancer therapy and its prospective molecular mechanisms of action are discussed. enInsulinMetforminprostate CancerdiabetesBook chapter